Revolutionizing Patient Care
It's in Our DNA
We discover, develop, and market transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Using state-of-the-art analytical equipment, automated specimen processing, and advanced reporting applications.
A Resource to Help you Deliver Optimal Patient Care
Designed specifically for healthcare professionals who are dedicated to making better, more informed clinical decisions and serving patients across the sequence of patient care.
patients & partners first
Industry Leading Testing
iQ Genetix Approach is Changing Infectious Disease Diagnostics
A symptom-driven diagnostic method that combines a broad grouping of probable pathogenic causes into a single, rapid test.
We help healthcare providers deliver proper treatment and reduce patient hospital stays by providing fast and accurate pathogen identification.
Our team leads the industry in infectious disease diagnostics and provides molecular solutions with many benefits.
With a same day turnaround for most of our tests, healthcare providers & clinicians can make vital decisions faster and more accurately.
We are committed to improving the quality of life for everyone, everywhere, and every day.
Our syndromic approach increases the probability of identifying a pathogen in patients with symptoms of an infectious disease.
The COVID-19 (SARS-CoV-2) test with iQ Genetix utilizing a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab.
There is limited information available to characterize the spectrum of clinical illness associated with COVID-19 but it likely spreads to others when a person shows signs or symptoms. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 4 days. Most patients with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing).
Please visit: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
The analytic sensitivity of the iQ Genetix PCR COVID-19 test was determined to be 100% in detecting known amounts of SARS-CoV-2 RNA with no cross reactivity to other known respiratory pathogens. A Not Detected (negative) test result for this test means that SARS-CoV-2 RNA was not present in the specimen above the manufacturer recommended cutoff value.
An interpretation indicating “Not Detected” does not rule out the possibility of COVID-19 and should not be used as the sole basis for treatment or patient management decisions. If COVID-19 is still suspected, based on exposure history together with other clinical findings, re-testing should be considered in consultation with public health authorities. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions.
Studies have been conducted on symptomatic patients; thus, it is unknown the exact exposure date for both symptomatic and asymptomatic patients. Studies show that asymptomatic patients begin shedding later after exposure* then symptomatic patients and then shed for a longer period of time. Additionally, asymptomatic patients also produce less antibodies.
You will receive the test results from iQ Genetix within 24-48 hours from the time of receipt at the laboratory.